Sarana Meditama Metropolitan (SAME) fair value: what the stock is really worth
As of Nov 6, 2026: fair value (intrinsic value) of Sarana Meditama Metropolitan stock IDR 42, price IDR 226, that is 81.2% below the price, quality 48 out of 100. Rating: strongly overvalued. Calculated from audited financials with 22 of our 26 valuation models and 37 quality factors, updated daily.
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 8, 2026.
How to read this chart
60‑month range 220.00 IDR – 705.00 IDR · fair‑value band 26.08 IDR – 61.63 IDR · the 226.00 IDR price screens above the 42.49 IDR fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). 1 fiscal year is left out: there the valuation rested on only a fraction of the usual models. As of Nov 8, 2026.
Follow Sarana Meditama Metropolitan in your weekly email
Every Wednesday you see whether Sarana Meditama Metropolitan is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
PT Sarana Meditama Metropolitan Tbk engages in the hospital management of EMC Hospital Pulomas in Pulomas, East Jakarta. The company operates specialty centers. It also is involved in trading of medical equipment; healthcare pharmacy; real estate; and agriculture.
Show moreShow less
The company was founded in 1984 and is based in Jakarta, Indonesia. PT Sarana Meditama Metropolitan Tbk is a subsidiary of PT Elang Mahkota Teknologi Tbk.
Stock analysis
Sarana Meditama Metropolitan (SAME) currently trades at 226.00 IDR, while our model-based Fair Value estimate is 42.49 IDR, 81% below the price, so the stock looks overvalued today.
Show more
Valuation
Bull case: the Asset-Based group reads highest at a median of 127.24 IDR per share, and 3 of the 22 models we run sit above the 226.00 IDR price.
Bear case: the Earnings-Based group reads lowest at 28.32 IDR, and 19 of the 22 models stay below the price. Data coverage for this calculation is low.
Scenario range: 26.08 IDR (bear) to 61.63 IDR (bull), the price of 226.00 IDR sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 48/100 (below-average quality), in the Healthcare sector.
Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Sarana Meditama Metropolitan reported revenue of 1.9T IDR in FY2025 versus 1.3T IDR in FY2021, a compound +10.0%/yr. Reported net income was 30.1B IDR in FY2025, compounding −32.4%/yr from FY2021.
Key figures
Market cap 3.9T IDR (≈ $215M) Micro · P/E ratio 191.5 · P/S ratio 1.96 · EPS (TTM) 1.18 IDR · Net margin 1.1% · Return on equity 0.7% · Return on assets (EBIT) 1.9% (5-year average) · Operating margin 5.0%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 25 out of 100 (low confidence).
What moves the price
The share trades about 47% below its 52-week high and at its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −1% fair-value upside, at −81%, SAME screens richer than that median.
Fair Value models
The price assumes far more growth than our models allow for, so the models scatter widely (19.16 IDR to 334.18 IDR). Read the Fair Value as a cautious anchor, not a price target; the Growth Forecast section shows what the price assumes.
Bear26.08 IDRFair Value 42.49 IDRBull61.63 IDR
Price 226.00 IDR · Downside -81.2%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Based on fiscal year 2025 figures (about 10 months old). Earnings retained since then (1.01 IDR per share) are deliberately not added.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.62/100
The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Revenue growth 1 year
+9.1%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+10.1%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+29.7%
Start year 2020 (pandemic). Over 10 years: +13.7% a year
Revenue growth 16 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+17.4%
’14
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
What shareholders gained per year (last 5 years), in IDR (mathematically smoothed) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Smoothed = median of all growth paths between the years of the window (trend line on the logarithm of earnings per share): a single extreme year cannot distort the rate. The reported figure stays in the tooltip. Measured in IDR: this currency has depreciated against the euro and dollar over the long run, so part of the nominal rate is currency erosion that never reaches a EUR/USD investor.
+3.6%
Earnings growth per share plus dividend.
Earnings per share, growth per year+3.6%
Dividend (yield on the price)0.0%
Pace: 5 vs 10 years ⓘTwo data points, not a trend model: earnings growth per share over the last 5 fiscal years against the last 10. Labelled "steady" when both rates are within 3 percentage points of each other, otherwise picking up or flattening. Shown only when ten years of history exist.−30.3% vs −11.9%, slowing
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.2% → 6%
2025 sits 154% above its own trend. The rate follows the median trend of the last 5 years, not that single year.
Pace: the 5-year rate starts in 2020 (pandemic)
Growth Forecast
A lot of optimism in the price
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
more than +80 %
Yearly growth needed for the next five years to justify today's price.
Compare Sarana Meditama Metropolitan with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Care Facilities · 234 stocks
Beats the industry median on 3/13 measures
Overall it trails its industry peers.
Valuation
Quality Score48 · Below median
Fair Value upside−81.2% · Bottom 25%
Profitability
Return on equity (12 months)0.7% · Bottom 25%
Return on assets0.5% · Bottom 25%
Net margin (12 months)1.1% · Bottom 25%
Operating margin (12 months)5.0% · Below median
Growth and dividend
Revenue growth (quarter YoY)17.7% · Top 25%
Balance sheet
Debt / equity0.13× · Below median
Valuation Multiplesvs Medical Care Facilities median · lower = cheaper
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Is Sarana Meditama Metropolitan (SAME) overvalued or undervalued?
As of Nov 8, 2026, our model estimates a fair value of 42.49 IDR versus a price of 226.00 IDR, about 81% lower (overvalued).
What is the fair value of SAME?
Our model-based fair value for Sarana Meditama Metropolitan is 42.49 IDR (as of Nov 8, 2026), built from audited fundamentals. The current price: 226.00 IDR.
What is the quality score of SAME?
Sarana Meditama Metropolitan has a Quality Score of 48/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Sarana Meditama Metropolitan (SAME)?
Our model-based price target is the fair value of 42.49 IDR (as of Nov 8, 2026) from 22 valuation models. Cautious scenario 26.08 IDR, optimistic scenario 61.63 IDR. It is a calculation from audited fundamentals, not an analyst target.
What is the Sarana Meditama Metropolitan stock forecast for 2026?
Our models put fair value at 42.49 IDR, about 81% lower versus a price of 226.00 IDR (overvalued). Cautious scenario 26.08 IDR, optimistic scenario 61.63 IDR. The calculation is refreshed regularly with new filings.
What is the revenue of Sarana Meditama Metropolitan (SAME)?
Sarana Meditama Metropolitan reported trailing-twelve-month revenue of about 2.0T IDR (latest available figure, as of Nov 8, 2026).
What growth is priced into Sarana Meditama Metropolitan (SAME)?
For today's price to be fair in a discounted-cash-flow model, Sarana Meditama Metropolitan would have to grow free cash flow by more than 80 % per year for five years (discount rate 13.5 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +29.7 % per year. As of Nov 8, 2026.
What discount rate (WACC) does the fair value of SAME use?
Our models discount Sarana Meditama Metropolitan at 13.5 %: a base by market capitalisation (micro), damped by beta 0.03, country premium for Indonesia. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Sarana Meditama Metropolitan that is more than 80 % per year for five years, then slowing evenly to 2 % by year ten, using the same discount rate (13.5 %) and the same formula as our fair value.
How much growth has Sarana Meditama Metropolitan (SAME) delivered so far?
Over the past 5 years revenue at Sarana Meditama Metropolitan grew +29.7 % a year. The price currently implies free-cash-flow growth of more than 80 % per year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Sarana Meditama Metropolitan (SAME) growing?
The median revenue growth in the sector is +6.2 % a year. That is the yardstick for the growth priced into Sarana Meditama Metropolitan (more than 80 % per year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Sarana Meditama Metropolitan (SAME)?
The free-cash-flow yield on the price is 0.38 %: that much free cash flow Sarana Meditama Metropolitan produces per unit of market value. When it exceeds the discount rate of our models (13.5 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Sarana Meditama Metropolitan (SAME)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Sarana Meditama Metropolitan it is 42.49 IDR per share (as of Nov 8, 2026), against a price of 226.00 IDR. It is the blended result of 22 valuation models in 7 families (DCF Models, Earnings-Based, Multiples, Asset-Based, Growth DCF, Economic Profit, Growth Earnings).
Is Sarana Meditama Metropolitan stock overvalued or undervalued in 2026?
As of Nov 8, 2026, SAME trades above its calculated fair value: price 226.00 IDR, fair value 42.49 IDR, a gap of about −81% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of SAME?
No. The price is what the market pays today (226.00 IDR); the fair value is what the company's own numbers justify (42.49 IDR). For Sarana Meditama Metropolitan the two are 183.51 IDR per share apart. That gap is exactly why we show both numbers side by side.
How much is Sarana Meditama Metropolitan worth?
The market values Sarana Meditama Metropolitan at about 3.9T IDR (market capitalisation, as of Nov 8, 2026). Per share that is 226.00 IDR; our models calculate a fair value of 42.49 IDR per share.
What do the bullish and bearish scenarios say about SAME?
Our models span a range for Sarana Meditama Metropolitan: cautious scenario 26.08 IDR, base 42.49 IDR, optimistic 61.63 IDR per share (as of Nov 8, 2026, price 226.00 IDR). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of SAME?
Sarana Meditama Metropolitan trades at a price-to-earnings ratio of 191.5 (as of Nov 8, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of 42.49 IDR is built from several models across several years. Median P/E at fiscal year-end, 7 fiscal years (2017 to 2025), reported earnings: 206.5. Other multiples: P/B 1.0, P/S 2.0, EV/EBITDA 11.8.
How solid is the balance sheet of Sarana Meditama Metropolitan (SAME)?
Balance-sheet figures for Sarana Meditama Metropolitan (as of Nov 8, 2026): return on equity 0.7%, debt of 0.13 per unit of equity. They feed the Quality Score of 48/100, which measures business quality independently of the share price.
How far is SAME from its 52-week high?
Sarana Meditama Metropolitan trades at 226.00 IDR, about 47% below its 52-week high of 428.00 IDR and at the low of 226.00 IDR (as of Nov 6, 2026). Distance from the high says nothing about value: that is what the fair value of 42.49 IDR is for.
Which stocks are comparable to Sarana Meditama Metropolitan?
From the same area (Healthcare) we also value HCA Healthcare, Inc, Fresenius SE, Tenet Healthcare Corporation, Dr. Sulaiman Al Habib Medical Services Group, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Sarana Meditama Metropolitan stock attractive at the current price?
The data as of Nov 8, 2026: price 226.00 IDR, calculated fair value 42.49 IDR (−81%), Quality Score 48/100, from 22 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of SAME calculated?
We run Sarana Meditama Metropolitan through 22 models from 7 families: DCF Models, Earnings-Based, Multiples, Asset-Based, Growth DCF, Economic Profit, Growth Earnings. Every model gets the same audited fundamentals; the fair value of 42.49 IDR builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.3% above its aggregate fair value. Sarana Meditama Metropolitan itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Sarana Meditama Metropolitan (SAME)?
The closing price on Nov 6, 2026 was 226.00 IDR. Our model-based fair value is 42.49 IDR, about 81% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Sarana Meditama Metropolitan right now?
The price sits above even our optimistic bull case (61.63 IDR). The favourable scenario is already priced in. Weak quality (48/100) and above fair value at the same time, the margin of safety is missing on both counts. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. A fairly wide model range (26.08 IDR to 61.63 IDR) leaves room in how you read the outcome.
Where does the earnings growth of Sarana Meditama Metropolitan (SAME) come from?
Earnings per share at Sarana Meditama Metropolitan grew −15.4 % a year from 2014 to 2025. Broken into its drivers: revenue per share +6.2 %, EBIT margin −13.6 %, tax rate −3.0 %, residual (interest, one-offs) −4.9 %. The four rates multiply to the earnings growth rate, they do not add up. Start and end are three-year averages so a single exceptional year does not distort the result.
Key figures of Sarana Meditama Metropolitan
How large is the market capitalisation of Sarana Meditama Metropolitan (SAME)?
The market capitalisation of Sarana Meditama Metropolitan is 3.9T IDR (≈ $215M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Sarana Meditama Metropolitan (SAME)?
The price-to-sales ratio of Sarana Meditama Metropolitan is 1.96 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Sarana Meditama Metropolitan (SAME)?
Earnings per share at Sarana Meditama Metropolitan are 1.18 IDR (price ÷ EPS = P/E 191.5). Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Sarana Meditama Metropolitan (SAME)?
The net margin of Sarana Meditama Metropolitan is 1.1% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Sarana Meditama Metropolitan (SAME)?
The return on equity (ROE) of Sarana Meditama Metropolitan is 0.7% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Sarana Meditama Metropolitan (SAME)?
On an EBIT basis the return on assets of Sarana Meditama Metropolitan is 1.9% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Sarana Meditama Metropolitan (SAME)?
The operating margin of Sarana Meditama Metropolitan is 5.0% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Sarana Meditama Metropolitan (SAME)?
Revenue at Sarana Meditama Metropolitan is growing +17.7% versus a year earlier (3y avg +10.1%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Sarana Meditama Metropolitan (SAME)?
Earnings per share at Sarana Meditama Metropolitan are growing +44.1% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net debt does Sarana Meditama Metropolitan (SAME) carry?
The net debt of Sarana Meditama Metropolitan is 826B IDR (fiscal year 2025, ≈ 55.5 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch Sarana Meditama Metropolitan in the live analysis
One click puts Sarana Meditama Metropolitan on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Thin data
Nov 8, 2026